Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bone marrow-derived cell therapy has been investigated in patients with severe liver disease. AIMS: To assess the feasibility, safety and cell kinetics of autologous bone marrow-derived mononuclear cells (BMMCs) infusion in cirrhotic patients. METHODS: BMMCs were isolated from autologous bone marrow and 10% of the cells were labelled with (99m)Tc-SnCl₂. Whole body scintigraphy (WBS) was performed 3 and 24 h after infusion via the hepatic artery. Liver function and image were followed during 1 year. RESULTS: Eight patients received 2.0-15.0 × 10⁸ cells. Three and 24-h WBS showed mean hepatic radiotracer retentions of 41 and 32% respectively. One case of dissection of the hepatic artery and one case of Tako-tsubo syndrome occurred as early complications. A patient developed a cutaneous immunomediated disorder and another patient developed hepatocellular carcinoma (HCC) 12 months after infusion. A reduction in bilirubin was shown at 1 week while serum albumin increased above baseline up to 1 month after infusion (P<0.05). CONCLUSIONS: BMMCs infusion is feasible and practical in a clinical setting. In vivo tracking of labelled cells demonstrated that the hepatic artery route successfully delivered BMMCs to the liver. The early improvement of laboratory indices of liver function should be interpreted with caution, because this study was not designed to evaluate efficacy. The median Model for End-Stage Liver Disease score had not deteriorated 1 year later. The occurrence of a graft-versus-host disease-like phenomenon highlights the importance of sustained vigilance even when giving autologous cells. Controlled studies are needed to determine whether BMMCs infusion affects HCC development in cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893 · cited 1×
“Patients were eligible for inclusion if they were between 18 and 75 years of age, and presented with cirrhosis with moderate liver dysfunction, defined as a Child–Pugh score (12) of B7 to C10 and a Model for End-Stage Liver Disease (MELD) score (13) below 20.”
Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 13×
“There are two major types of adult stem cells in the bone marrow: haematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs).”
BackgroundInfluentialYannaki, E., Anagnostopoulos, A., Kapetanos, D., Xagorari, A., Iordanidis, F., Batsis, I., Kaloyannidis, P., Athanasiou, E., Dourvas, G., Kitis, G., et al. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.012 · Cited by 101
Cited by
Lu, W., Qu, J., Yan, L., Tang, X., Wang, X., Ye, A., Zou, Z., Li, L., Ye, J., & Zhou, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03518-x · Cited by 49
Nguyen, T. L., Nguyen, H. P., Ngo, D. M., Ha, T. H. T., Mai, K. A., Bui, T. H., Nguyen, P. V., Pham, L. H., Hoang, D. M., & Cao, A. D. T. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02762-x · Cited by 19
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
Metadata
- Authors
- Couto, B. G., Goldenberg, R. C. D. S., da Fonseca, L. M. B., Thomas, J., Gutfilen, B., Resende, C. M. C., Azevedo, F., Mercante, D. R., Torres, A. L. M., Coelho, H. S. M., Maiolino, A., Alves, A. L. D. A., Dias, J. V., Moreira, M. C. R., Sampaio, A. L. S. B., Sousa, M. A. J., Kasai-Brunswick, T. H., Souza, S. A. L., Campos-de-Carvalho, A. C., & Rezende, G. F. D. M.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2011-01-19
- Volume
- 31
- Issue
- 3
- Pages
- 391-400
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- OpenAlex
- W2157300041
- Cited by
- 67
- References
- 4
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis. https://app.cochat.ai/papers/10.1111/j.1478-3231.2010.02424.x
- The paper
- Couto, B. G., Goldenberg, R. C. D. S., da Fonseca, L. M. B., Thomas, J., Gutfilen, B., Resende, C. M. C., Azevedo, F., Mercante, D. R., Torres, A. L. M., Coelho, H. S. M., Maiolino, A., Alves, A. L. D. A., Dias, J. V., Moreira, M. C. R., Sampaio, A. L. S. B., Sousa, M. A. J., Kasai-Brunswick, T. H., Souza, S. A. L., Campos-de-Carvalho, A. C., & Rezende, G. F. D. M. (2011). Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis. Liver International. https://doi.org/10.1111/j.1478-3231.2010.02424.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.